Sidoti Has Negative Forecast for Kamada FY2026 Earnings

Kamada Ltd. (NASDAQ:KMDA) – Equities research analysts at Sidoti lowered their FY2026 earnings per share (EPS) estimates for shares of Kamada in a research note issued to investors on Friday, September 25th. Sidoti analyst J. Sidoti now expects that the biotechnology company will earn $0.42 per share for the year, down from their previous forecast of $0.46. The consensus estimate for Kamada’s current full-year earnings is $0.48 per share. Sidoti also issued estimates for Kamada’s FY2027 earnings at $0.46 EPS.

Kamada (NASDAQ:KMDA) last released its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.11 by $0.05. Kamada had a net margin of 11.60% and a return on equity of 8.37%. The business had revenue of $54.92 million during the quarter, compared to analyst estimates of $50.84 million.

KMDA has been the topic of several other reports. William Blair set a $15.00 price objective on Kamada in a research note on Tuesday, July 21st. Wall Street Zen upgraded Kamada from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 15th. UBS Group reiterated a “buy” rating and issued a $15.00 target price on shares of Kamada in a report on Friday, September 18th. Weiss Ratings reissued a “buy (b-)” rating on shares of Kamada in a research report on Tuesday, September 22nd. Finally, Benchmark restated a “buy” rating on shares of Kamada in a report on Tuesday, July 21st. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $13.50.

Kamada Trading Up 0.8%

Shares of NASDAQ:KMDA opened at $8.69 on Tuesday. Kamada has a 12 month low of $6.50 and a 12 month high of $9.35. The company has a 50-day moving average price of $7.93 and a 200 day moving average price of $7.89. The company has a market cap of $499.76 million, a price-to-earnings ratio of 22.87, a PEG ratio of 0.72 and a beta of 0.88.

Institutional Investors Weigh In On Kamada

A hedge fund recently raised its position in Kamada stock. Aristides Capital LLC raised its holdings in Kamada Ltd. (NASDAQ:KMDA) by 4.5% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 34,491 shares of the biotechnology company’s stock after acquiring an additional 1,476 shares during the quarter. Aristides Capital LLC owned approximately 0.06% of Kamada worth $288,000 as of its most recent filing with the Securities & Exchange Commission. 20.38% of the stock is currently owned by institutional investors.

Kamada Cuts Dividend

The firm also recently announced an annual dividend, which was paid on Thursday, September 17th. Stockholders of record on Thursday, August 27th were paid a dividend of $0.17 per share. This is a negative change from Kamada’s previous annual dividend of $0.25. This represents a dividend yield of 206.0%. The ex-dividend date of this dividend was Thursday, August 27th. Kamada’s payout ratio is currently 34.21%.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company focused on the development, manufacture and commercialization of plasma-derived and specialty pharmaceutical products. The company’s portfolio is aimed primarily at treating rare diseases and other conditions requiring replacement or immune-modulating therapies.

Kamada’s principal product is GLASSIA, an intravenous alpha-1 proteinase inhibitor used as augmentation therapy in adults with alpha-1 antitrypsin deficiency, a rare genetic disorder that can cause progressive lung disease.